Sionna Therapeutics has successfully completed enrollment for its PreciSION CF Phase 2a proof-of-concept trial, evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, in conjunction with the standard of care, Trikafta® (elexacaftor/tezacaftor/ivacaftor). This trial is particularly significant as it represents the first clinical investigation of an NBD1 stabilizer in cystic fibrosis (CF) patients, specifically targeting the F508del mutation, the most prevalent CF-causing genetic alteration.

The trial aims to assess the safety, tolerability, and pharmacokinetics of SION-719, while also measuring changes in sweat chloride levels, a key indicator of CFTR function. Conducted across multiple sites within the CF Foundation-supported Therapeutics Development Network, the trial’s outcomes could provide critical insights into the therapeutic potential of directly addressing the underlying defect in CFTR function, potentially leading to improved clinical outcomes and quality of life for individuals with CF.

The completion of enrollment marks a pivotal moment in CF research, suggesting a shift towards more targeted therapies that not only complement existing treatments but also aim to correct the fundamental defects caused by genetic mutations. If successful, Sionna’s approach could accelerate the development of next-generation CF therapies and reshape the treatment landscape, emphasizing the importance of NBD1 stabilization in restoring CFTR function. This could ultimately influence drug development timelines and strategies in the broader context of genetic diseases.

Source: globenewswire.com